Related Experiment Video
Updated: Aug 14, 2026
Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Published on: October 14, 2019
Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma
Miguel Cordova-Delgado1,2, Gonzalo Pizarro1, Mauricio P Pinto1
1Hematology and Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago, Chile.
Abstract:
Small bowel adenocarcinoma (SBA) is a rare malignancy characterized by poor prognosis. Recent efforts have sought to elucidate the genetic landscape and the molecular drivers behind this disease. Herein, we report the main molecular alterations in two metastatic (stage IV) SBA patients. Interestingly, one of them had gene alterations that affected signaling pathways previously described for SBA. However, a second patient displayed previously unreported alterations in this particular tumor type. Based on these findings we discuss potential treatment options for patients affected by this rare, aggressive disease.
Insights
Small bowel adenocarcinoma (SBA) is rare and aggressive. This study details molecular alterations in two metastatic SBA patients, revealing previously unreported genetic changes in one case, guiding potential treatments.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy with a generally poor prognosis.
- Understanding the molecular drivers of SBA is crucial for developing effective therapeutic strategies.
- Recent research focuses on identifying the genetic landscape of SBA to uncover potential therapeutic targets.
Observation:
- This study investigated the molecular alterations in two patients with metastatic (stage IV) small bowel adenocarcinoma.
- Genomic profiling was performed to identify key gene mutations and pathway dysregulations.
- Patient 1 exhibited molecular alterations consistent with previously described SBA pathways.
Findings:
- Patient 2 presented with novel, previously unreported molecular alterations in small bowel adenocarcinoma.
- The identified genetic changes in Patient 2 suggest distinct molecular subtypes within SBA.
- These findings expand the known molecular landscape of this rare cancer.
Implications:
- The identification of novel alterations in SBA opens new avenues for targeted therapy development.
- Understanding diverse molecular profiles can lead to personalized treatment approaches for SBA patients.
- This research contributes to the characterization of a rare and aggressive malignancy, potentially improving patient outcomes.
